AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) major shareholder Ravi Viswanathan acquired 184,179 shares of the stock in a transaction dated Thursday, May 17th. The shares were bought at an average price of $2.13 per share, for a total transaction of $392,301.27. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Ravi Viswanathan also recently made the following trade(s):
- On Tuesday, May 8th, Ravi Viswanathan acquired 70,873 shares of AVEO Pharmaceuticals stock. The shares were bought at an average price of $2.13 per share, for a total transaction of $150,959.49.
- On Friday, April 6th, Ravi Viswanathan acquired 685,676 shares of AVEO Pharmaceuticals stock. The shares were bought at an average price of $2.24 per share, for a total transaction of $1,535,914.24.
AVEO Pharmaceuticals opened at $2.35 on Thursday, Marketbeat.com reports. The company has a debt-to-equity ratio of -0.36, a quick ratio of 1.34 and a current ratio of 1.34. AVEO Pharmaceuticals, Inc. has a 52 week low of $0.63 and a 52 week high of $4.24. The firm has a market cap of $278.15 million, a P/E ratio of -14.69 and a beta of 1.41.
AVEO Pharmaceuticals (NASDAQ:AVEO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.01). The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.98 million. research analysts expect that AVEO Pharmaceuticals, Inc. will post -0.27 earnings per share for the current year.
Several analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, May 4th. BidaskClub raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, March 24th. Finally, ValuEngine raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $4.05.
Several hedge funds have recently added to or reduced their stakes in the stock. Prosight Management LP bought a new position in shares of AVEO Pharmaceuticals during the 4th quarter valued at $2,951,000. Point72 Asset Management L.P. grew its holdings in shares of AVEO Pharmaceuticals by 213.5% during the 1st quarter. Point72 Asset Management L.P. now owns 940,403 shares of the biopharmaceutical company’s stock valued at $2,727,000 after purchasing an additional 640,403 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of AVEO Pharmaceuticals by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 667,956 shares of the biopharmaceutical company’s stock valued at $1,863,000 after purchasing an additional 40,616 shares during the last quarter. Emory University bought a new position in shares of AVEO Pharmaceuticals during the 4th quarter valued at $1,682,000. Finally, Armistice Capital LLC bought a new position in shares of AVEO Pharmaceuticals during the 4th quarter valued at $1,674,000. 50.23% of the stock is currently owned by institutional investors.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.